Citadel Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-112,981
| Closed | -$5.84M | – | 16023 |
|
|
2022
Q3 | $5.84M | Sell |
112,981
-191,443
| -63% | -$7.91M | ﹤0.01% | 3618 |
|
|
2022
Q2 | $7.54M | Sell |
304,424
-1,906
| -0.6% | -$42K | ﹤0.01% | 3073 |
|
|
2022
Q1 | $7.68M | Sell |
306,330
-234,282
| -43% | -$6.58M | ﹤0.01% | 3392 |
|
|
2021
Q4 | $19.7M | Sell |
540,612
-419,075
| -44% | -$14.7M | ﹤0.01% | 2044 |
|
|
2021
Q3 | $16.4M | Buy |
959,687
+237,548
| +33% | +$3.7M | ﹤0.01% | 2287 |
|
|
2021
Q2 | $9.67M | Buy |
722,139
+378,759
| +110% | +$9.33M | ﹤0.01% | 3135 |
|
|
2021
Q1 | $17.6M | Sell |
343,380
-229,691
| -40% | -$13.8M | ﹤0.01% | 2131 |
|
|
2020
Q4 | $35.5M | Buy |
573,071
+114,846
| +25% | +$6.58M | 0.01% | 1240 |
|
|
2020
Q3 | $25.1M | Sell |
458,225
-300,013
| -40% | -$16.2M | 0.01% | 1380 |
|
|
2020
Q2 | $43.6M | Buy |
758,238
+23,813
| +3% | +$1.3M | 0.02% | 890 |
|
|
2020
Q1 | $29.5M | Buy |
734,425
+673,474
| +1,105% | +$28.6M | 0.01% | 946 |
|
|
2019
Q4 | $2.41M | Buy |
60,951
+45,935
| +306% | +$807K | ﹤0.01% | 4113 |
|
|
2019
Q3 | $102K | Buy |
+15,016
| New | +$113K | ﹤0.01% | 8474 |
|
|
2019
Q2 | – | Sell |
-26,133
| Closed | -$303K | – | 10099 |
|
|
2019
Q1 | $363K | Buy |
26,133
+6,360
| +32% | +$72.7K | ﹤0.01% | 7321 |
|
|
2018
Q4 | $215K | Sell |
19,773
-30,928
| -61% | -$326K | ﹤0.01% | 7767 |
|
|
2018
Q3 | $641K | Sell |
50,701
-45,926
| -48% | -$553K | ﹤0.01% | 6302 |
|
|
2018
Q2 | $1.27M | Buy |
96,627
+77,798
| +413% | +$930K | ﹤0.01% | 4806 |
|
|
2018
Q1 | $256K | Sell |
18,829
-38,294
| -67% | -$395K | ﹤0.01% | 6981 |
|
|
2017
Q4 | $340K | Buy |
57,123
+10,744
| +23% | +$73.7K | ﹤0.01% | 6248 |
|
|
2017
Q3 | $344K | Buy |
46,379
+33,871
| +271% | +$282K | ﹤0.01% | 5859 |
|
|
2017
Q2 | $117K | Sell |
12,508
-11,580
| -48% | -$85K | ﹤0.01% | 6853 |
|
|
2017
Q1 | $175K | Sell |
24,088
-17,406
| -42% | -$125K | ﹤0.01% | 6617 |
|
|
2016
Q4 | $307K | Buy |
+41,494
| New | +$299K | ﹤0.01% | 5637 |
|
|
2016
Q3 | – | Sell |
-67,085
| Closed | -$301K | – | 7946 |
|
|
2016
Q2 | $301K | Sell |
67,085
-3,668
| -5% | -$13.8K | ﹤0.01% | 5221 |
|
|
2016
Q1 | $176K | Buy |
70,753
+31,652
| +81% | +$115K | ﹤0.01% | 5733 |
|
|
2015
Q4 | $316K | Buy |
+39,101
| New | +$277K | ﹤0.01% | 5141 |
|
|
2014
Q3 | – | Sell |
-7,857
| Closed | -$46K | – | 8513 |
|
|
2014
Q2 | $46K | Buy |
+7,857
| New | +$44.1K | ﹤0.01% | 6800 |
|
Other funds holding CCXI
Citadel Advisors's CCXI Position: Q4 2022 in Review
Citadel Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 112,981 shares — an estimated $5.84M sold.
Citadel Advisors first reported a position in CCXI in Q2 2014 and held it in 27 quarters. The position peaked at $43.6M in Q2 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Citadel Advisors reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 112,981 ChemoCentryx, Inc. shares in Q4 2022, an estimated $5.84M.
- Citadel Advisors first reported a position in ChemoCentryx, Inc. in Q2 2014 and held it in 27 quarters.
- Citadel Advisors's ChemoCentryx, Inc. position peaked at $43.6M in Q2 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.